Anesthesia management of patients posted for resection of rhino-orbital mucormycosis developed as a postCovid sequale: Sharing our experiences

Ansari Azra Jabeen Wahab

doi:10.15713/ins.bhj.89

Authors

Ansari Azra Jabeen Wahab Global hospital, Parel

DOI:

https://doi.org/10.15713/ins.bhj.89

Keywords:

Amphotericin B, anaesthesia management, covid-19, mucormycosis

Abstract

Background: Although Mucormycosis is a rare life-threatening fungal infection mainly seen in immunocompromised patients, there has been increasing number of mucormycosis cases presenting as a post COVID sequale mainly from India. Uncontrolled diabetes and overzealous use of steroid seems to be two main aggravating factors. Aggressive medical and surgical management of mucormycosis decreases mortality rate from 88% to 21%.

Aim: This study is aimed to evaluate anaesthetic challenges in the post COVID patients coming for surgical clearance of mucormycosis.

Demographic characteristics, associated comorbidities, procedural data, surgical details, hospital stay and mortality rates were reviewed in 32 patients. The mean age of our patients was 52.66 yrs. and 96.9% had associated comorbidities. Two (6.3%) patients had mallampati classification (MPC) IV and 12 had III (40.6%). Average anaesthesia duration was 282.5 min with mean blood loss 792 ml. Twenty-one (65.6%) patients were shifted to ICU (intensive care unit) out of which 15 (46.87%) were electively ventilated. Mortality was seen in 2 patients with mortality rate of 6.25%.

Conclusion: Surgical resection of mucormycosis in post covid patients presents unique challenges – associated comorbidities, difficult airway, prolonged surgical duration, intraoperative hemodynamic instability massive blood loss, Amphotericin B related side effects mainly nephrotoxicity and hypokalemia, need for postoperative ventilation and prolonged hospital stay. Preoperative optimization, careful intraoperative monitoring and postoperative management are necessary for better outcome.

References

Karaaslan E. Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on

challenges. J Mycol Med. 2019 Sep;29(3):219-222. doi: 10.1016/j.mycmed.2019.07.001. Epub 2019 Jul 26. PMID: 31399350.

Spellberg B, Edwards Jr. J, Ibrahim A. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin Microbiol Rev 2005;556-69.

Kulkarni PK, Reddy NB, Shrinivas B, Takkalki VV. Anesthetic considerations in the management of mucormycosis. International Journal of Medicine and Public Health. 2015;5(4):387-390.

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330–1341.

doi:10.1001/jama.2020.17023

John, Teny& Jacob, Ceena& Kontoyiannis, Dimitrios. (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of fungi (Basel, Switzerland). 7. 10.3390/jof7040298.

Satish D, Joy D, Ross A, Balasubramanya. Mucormycosiscoinfection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg 2021;7:815-20.

Eckmann DM, Seligman I, Cote´ CJ, Hussong JW. Mucormycosissupraglottitis on induction of anesthesia in an immunocompromised host. AnesthAnalg 1998;86:729–30.

Barodka VM, Acheampong E, Powell G, Lobach L, Logan DA, Parveen Z, et al. Antimicrobial effects of liquid anesthetic isoflurane on Candida albicans. J Transl Med 2006;9:46.

Jeong SJ, Lee JU, Song YG, Lee KH, Lee MJ. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. Mycoses 2015;58:746–52.